2 billion plus shares, approximately 137 million total cost which is ONE 47TH of what PFIZER PHARMA spends in ONE YEAR on research and development. PFIZER spends 8 BILLION a year on R and D, so ACTC'S outstanding shares look quite attractive to any big pharma looking for a JV. ACTC'S outstanding shares are pocket change compared to the overall spending by big pharma on research annually. Hey, don't ever go to work in a haunted house goldi, you'll never scare anyone. LOL..